Viral Vector Manufacturing Global Market Report 2023 – By Type (Adenoviral Vectors, Adeno-Associated Viral Vectors, Lentiviral Vectors, Retroviral Vectors, Other Types), By Disease (Cancer, Genetic Disorders, Infectious Diseases, Other Diseases), By Workflow (Upstream Processing, Downstream Processing), By Application (Gene And Cell Therapy Development, Vaccine Development, Biopharmaceutical And Pharmaceutical Discovery, Biomedical Research), By End-User (Research Organizations, Biotech And Pharmaceutical Companies, Others End Users) – Market Size, Trends, And Global Forecast 2023-2032

Recombinant DNA technology refers to fusing DNA molecules from other organisms and inserting those DNA molecules into a host organism to build a new genetic combinations useful for science, medicine, agriculture, and industry. The recombinant DNA technology is used to address health issues by creating new medications and vaccines. The main product type of recombinant DNA technology include recombinant protein drugs, vaccines, genetically modified crops, expression systems, cell and gene therapy and gene editing. The recombinant protein drugs are used in the biochemical analysis as well as medical diagnostic reagents in human healthcare, such as antibodies, medicines, or vaccines. Recombinant protein drugs are referred to as highly potent medicines that develop faster than small molecules and are safe from off-target negative effects. The component type include expression system and cloning vector. The recombinant DNA technology is applied in food and agriculture, health and disease, environment and other applications and used in biotechnology and pharmaceutical companies, academic and government research institutes and other end-use industries. The global recombinant DNA technology market is segmented - 1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell and Gene Therapy, Gene Editing 2) By Component Type: Expression System, Cloning Vector 3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types 4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types The global recombinant DNA technology market size is expected to grow from $754.97 billion in 2022 to $811.89 billion in 2023 at a compound annual growth rate (CAGR) of 7.54%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The recombinant DNA technology market size is expected to reach $1,069.51 billion in 2027 at a CAGR of 7.13%. The increasing number of chronic diseases is expected to propel the growth of the recombinant DNA technology market. Chronic diseases, which are defined as ailments that last for a year or longer, necessitate continuing medical care, restrict everyday activities, or both. Recombinant DNA technology has improved healthcare by creating biopharmaceuticals proteins used in pharmaceuticals and by replacing defective genes with healthy ones through gene therapy, aiming to cure illness. For instance, in April 2021, according to a report shared by WHO, a Switzerland-based specialized agency of the United Nations responsible for international public health, noncommunicable diseases (NCDs) accounted for 41 million annual deaths, or 71% of all deaths worldwide. Between the ages of 30 and 69, more than 15 million people per year die from an NCD; 85% of these premature deaths take place in low- and middle-income nations. Therefore, the increase in chronic diseases is driving the growth of the recombinant DNA technology market. Major players in the recombinant DNA technology market are Profacgen, Amgen Inc., Novartis AG, GenScript, Pfizer Inc., Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Merck & Co. Inc., Biogen, GlaxoSmithKline PLC., New England Biolabs, Monsanto Company, Thermo Fisher Scientific, Inc., and F. Hoffmann-La Roche Ltd. Technological advancement is a key trend in the recombinant DNA technology market. Major companies operating in the recombinant DNA technology market are focused on innovative technologies to sustain their position in the market. For instance, in October 2021, Thermo Fisher Scientific, a US-based supplier of scientific instrumentation, reagents and consumables, and software services, introduced the Applied Biosystem QuantStudio Absolute Q-Digital PCR System, the first fully integrated digital PCR (dPCR) equipment made to deliver extremely precise and reliable findings in genetic analysis and research in less than 90 minutes. The QuantStudio Absolute Q System uses microfluidic array technology and streamlined processes instead of the complicated, multi-instrument workflows necessary for standard dPCR, which is intended to increase data accuracy and consistency. The QuantStudio Absolute Q solution is a quick and easy workflow that provides high-quality data with the least amount of manual labour. It combines the data collection, heat cycling, and digitization processes required for dPCR into a single device. In January 2022, Thermo Fisher Scientific, a US-based scientific instrumentation supplier, reagents, consumables, and software services, acquired PeproTech for $1.85 billion. The acquisition complements Thermo Fisher's cell culture media products with PeproTech's recombinant proteins portfolio, which is expected to allow Thermo Fisher to give customers significant advantages through an integrated offering. PeproTech, Inc. is a US-based developer and manufacturer of bioscience reagents known as recombinant proteins. North America was the largest region in the recombinant DNA technology market share in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant DNA technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the Recombinant DNA Technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The recombinant DNA technology market includes revenues earned by entities by expression systems including mammalian, bacteria, yeast, and baculovirus / insect. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The recombinant DNA technology market research report is one of a series of new reports from The Business Research Company that provides recombinant DNA technology market statistics, including recombinant DNA technology industry global market size, regional shares, competitors with an recombinant DNA technology market share, detailed recombinant DNA technology market segments, market trends and opportunities, and any further data you may need to thrive in the recombinant DNA technology industry. This recombinant DNA technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Protein expression is a process in which proteins are synthesized, modified, regulated, and controlled in living organisms according to the host cell. Protein expression in the context of protein research can now also refer to the application of lab procedures necessary for protein production. The main product types for protein expression are reagents, competent cells, expression vectors, services, and instruments. A reagent is a substance or compound that is added to a system in order to produce a chemical reaction or to determine whether or not a reaction occurred. The various forms of protein expression include yeast expression, mammalian expression, algae expression, insect expression, bacterial expression, and cell-free expression that are used for therapeutic, industrial, and research applications. The different end users involve pharmaceutical and biotechnology companies, academic research, and contract research organizations. The global protein expression market is segmented - 1) By Protein Expression: Yeast Expression, Mammalian Expression, Algae Expression, Insect Expression, Bacterial Expression, Cell-free Expression 2) By End Use: Pharmaceutical And Biotechnological Companies, Academic Research, Contract Research Organizations 3) By Product: Reagents, Competent Cells, Expression vectors, Services, Instruments 4) By Application: Therapeutic, Industrial, Research The global protein expression market size will grow from $2.87 billion in 2022 to $3.19 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global protein expression is expected to grow to $4.96 billion in 2027 at a CAGR of 11.6%. An increase in demand for biologics to counter various genetic disorders and chronic diseases is one the major factors driving the research and sales of protein expression market. Biologics is a medicine produced from living organisms or contains components of living organisms such as protein, tissue, genes, allergens, cells, blood components, blood, and vaccines. The increasing use of biologics (therapeutic protein and others) to cure chronic diseases such as cancer, cardiovascular conditions and genetic disorders, is increasing the demand for protein expression devices and equipment. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. Hence the rising demand for biologics is driving the protein expression market. For instance, according to an article published by Chemistry World, analysts stated that the biologics market hold a market share of more than a quarter of the entire pharmaceutical market in 2020. The global biologics market is expected to grow at 14.7% during 2021-2023. Major players in the protein expression market are Agilent Technologies, Bio-Rad Laboratories, Thermo Fisher Scientific Inc., New England Biolabs, Promega Corporation, Qiagen, Takara Bio, Merck KGaA, Genscript Biotech Corporation, Life Technologies Corporation, Sigma-Aldrich Corporation, Lucigen Corporation, Synthetic Genomics Inc., Becton, Dickinson & Company, Lonza Group Ltd., Accelagen Inc., Geneva Biotech, Viva Biotech, Becton, Dickinson & Company, Sengenics, ARTES Biotechnology GmbH, Addgene Inc., Profacgen, ProteoGenix, Peak Proteins Ltd., Domainex Ltd., Jena Bioscience GmbH, EMD Millipore, and Oxford Expression Technologies Ltd. Government regulations related to protein therapeutics and the production of biologics may hinder the protein expression market growth. Government regulations on biologics to undergo rigorous preclinical and clinical trials prior to regulatory approval, and time-consuming process for approval of biologics with regards to health and the safety of any individual are restraining the market growth. Marketing and distribution of biologics including insulin, hormones, therapeutic antibodies, and vaccines depends upon the successful completion of clinical trials, which is a long, expensive, and uncertain process. According to FDA, for an approval of new biologic, Under the regulations (21 CFR 314.81(b)(2)(vii) and 601.70, a clinical trial approval usually takes 10- 12 months where firms are required to submit a report annually on the status of clinical safety, clinical efficiency, clinical pharmacology, and nonclinical toxicology study. Companies in the industry are increasingly adopting Microfluidics technology to enhance protein expression tests in order to reduce the time, cost, labor, and increase in the accuracy and performance. The microfluidics technology effectively analyzes biological samples than the traditional (macroscale) instruments. Microfluidics technology is used to measure the expression of proteins on cells and optimizes the output to generate results regarding protein expression. Therapeutics-on-a-chip (TOC) uses microfluidic platform and is able to synthesize proteins in a point-of-care setting to reduce cost associated with storage and transportation of therapeutic proteins. For instance, companies such as MissionBio, NanoCellect Biomedical, RainDance Technologies and Sphere fluidics have implemented this technology in protein expression test. The Protein Expression market in the U.S. is governed by the Food and Drug Administration (FDA) which lays down a series of guidelines for the manufacturers and retailers of this industry. Within FDA, Centre for Drug Evaluation and research (CDER) regulates biological products under FDA 101 which includes gene therapy products and vaccines. These regulations ensure the quality, safety, and efficacy of biological therapeutics products, and speed up innovations that make these products safer, and effective. The US FDA announced a fast-track initiative to review its drugs and biologics policy to speed the availability of therapies to patients with serious conditions, orphan drugs for rare disease, while preserving the safety and efficacy standards. FDA also removed a rule (Section 610.21 of the FDA code) that specified minimal potency limits for certain antibodies and antigens. The European Medicines Agency has also introduced policies that include a provision to waive the scientific advice fee, which encourages more academic groups and small companies to propose candidates for biologics. North America was the largest region in the protein expression market in 2022. Western Europe was the second largest region in the global protein expression market share. The regions covered in the global protein expression market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the protein expression market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The protein expression market includes revenue earned by instruments, expression kits, and systems. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The protein expression market research report is one of a series of new reports from The Business Research Company that provides protein expression market statistics, including protein expression industry global market size, regional shares, competitors with a protein expression market share, detailed protein expression market segments, market trends and opportunities, and any further data you may need to thrive in the protein expression industry. This protein expression market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene therapy refers to a method for treating or curing sickness that alters a person's DNA. Gene treatments can function in a variety of ways: putting a healthy copy of the gene in place of a disease-causing gene, and putting a defective gene that causes an illness inactive. The main types of gene therapy are antigens, cytokines, suicide genes, and others. The antigen is a poison or other foreign substance that triggers an immunological response in the body, including antibody formation. The different vectors include viral vectors, non-viral vectors, and others and are used in oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious diseases, and others. it is implemented in various sectors, such as hospitals, homecare, specialty clinics, and others. The global gene therapy market is segmented - 1) By Gene Type: Antigen, Cytokine, Suicide Gene, and Other Gene Types 2) By Vector: Viral Vector, Non-Viral Vector, Other Vectors 3) By Application: Oncological Disorders, Rare Diseases, Cardiovascular Diseases, Neurological Disorders, Infectious Diseases, Other Applications 4) By End Users: Hospitals, Homecare, Specialty Clinics, Other End-Users The global gene therapy market grew from $7.37 billion in 2022 to $9.42 billion in 2023 at a compound annual growth rate (CAGR) of 27.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of gene therapy is expected to grow from $24.03 billion in 2027 at a CAGR of 26.4%. Incidences of cancer and other target diseases have been increasing significantly, which is calling for effective treatments, driving the growth of the gene therapy market. The rise in the number of cancer cases across the globe is likely to contribute to the growth of the gene therapy market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Therefore, the rise in the cancer incidence rate globally is anticipated to boost the demand for the gene therapy market over the forthcoming years. Gene therapy is one of the most effective treatments in oncology. In this treatment, new genes are introduced into a cancerous cell or the surrounding tissue to cause cell death or slow the growth of cancer. Major players in the gene therapy market are Novartis AG, Bluebird Bio Inc., Spark Therapeutics Inc., Audentes Therapeutics, Voyager Therapeutics, Applied Genetic Technologies Corporation, UniQure N.V., Celgene Corporation, Cellectis S.A., and Sangamo Therapeutics. The high prices of gene therapy medicines are expected to limit the growth of the gene therapy market. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, the lack of cost-effective therapies for cancer and other diseases has influenced the health conditions of the population and led to a low average life expectancy. Luxturna, a one-time treatment for acquired retinal eye disease, costs $850,000 in the US and £613,410 in the UK, despite a markdown that is applied through Britain's National Health Service. Zolgensma, for spinal muscular atrophy, is valued at $2.1 million in the US, while Zynteglo, which focuses on a rare genetic blood disorder, costs $1.78 million, thus restraining the growth of the market. The use of machine learning and artificial intelligence is gradually gaining popularity in the gene therapy market. Artificial intelligence (AI) is the simulation of human intelligence in machines, which are programmed to display their natural intelligence. Machine learning is a part of AI. Machine learning and AI help companies in the gene therapy market conduct a detailed analysis of all relevant data, provide insights between tumour and immune cell interactions, and offer a more accurate evaluation of tissue samples, which is often disputed between different evaluators. For instance, since January 2020, GlaxoSmithKline, a pharmaceutical company, has been investing in AI to optimise gene therapy and develop off-the-shelf solutions for patients. It is also expected to reduce turnaround time and the cost of gene therapies. In December 2021, Novartis AG, a Switzerland-based pharmaceutical company specialising in the discovery, development, manufacturing, and commercialization of medicines, acquired Gyroscope Therapeutics Holdings plc for an amount of $800 million. Through this acquisition, GT005, an experimental, one-time gene therapy now in Phase 2 for the treatment of persons with geographic atrophy (GA), will be added to the Novartis portfolio, increasing gene therapy research capabilities and bringing ophthalmic innovation to treat and prevent blindness globally. Gyroscope Therapeutics Holdings plc is a UK-based clinical stage biopharmaceutical company pioneering in the research and development of gene therapies for the treatment of eye related diseases. North America was the largest region in the gene therapy market in 2022. The regions covered in the gene therapy market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The gene therapy market includes revenues earned by entities by replacing a disease-causing gene with a healthy copy of the gene and inactivating a disease-causing gene that is not functioning properly. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The gene therapy market research report is one of a series of new reports from The Business Research Company that provides gene therapy market statistics, including gene therapy industry global market size, regional shares, competitors with a gene therapy market share, detailed gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy industry. This gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Viral vectors refer to a tool made of a viral genome that has been converted into a plasmid-based technology, modified for safety by deleting several necessary genes, and the viral components have been separated. Whereas, Plasmid DNA refers to a tiny, circular DNA molecule that can be found in some bacteria and other tiny organisms. Physically distinct from chromosomal DNA, plasmids multiply on their own. The main types of products in viral vectors & plasmid DNA are plasmid DNA and viral vectors. A plasmid is a single-stranded, circular DNA molecule that is different from the chromosomal DNA of a cell. Plasmids are found organically in bacterial cells as well as in certain eukaryotes. Plasmid genes frequently confer genetic benefits to bacteria, such as antibiotic resistance. The different diseases include infectious diseases, genetic disorders, cancer, and others, and are used in gene and cancer therapies, viral infections, immunotherapy, formulation development, and others. The several sectors include research institutes, biopharmaceutical companies, and pharmaceutical companies. The global viral vectors and plasmid dna market is segmented - 1) By Product: Plasmid DNA, Viral Vectors 2) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications 3) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases 4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies The global viral vectors & plasmid dna market size grew from $0.8 billion in 2022 to $0.91 billion in 2023 at a compound annual growth rate (CAGR) of 14.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the viral vectors & plasmid dna is expected to grow from $1.47 billion in 2027 at a CAGR of 12.6%. The rise in the global incidence of cancer is driving the viral vector and plasmid DNA market. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. According to the American cancer society 2020, an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States.Furthermore, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases.The rise in the global incidence of cancer is expected to boost the demand for the viral vectors and plasmid DNA market over the coming years. Major players in the viral vectors & plasmid DNA market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k???r??r?t??n, Cell and Gene Therapy Catapult, VGXI and MassBiologics. The unaffordable cost of gene therapies is a major challenge in the viral vectors and plasmid DNA market. The prices of gene therapies range from $0.2 million to $2.1 million. For instance, Gilead company's Yescarta is a gene therapy that costs around $0.3 million and Bluebird Bio's Letiglobin is another gene therapy costing around $2.1 million. The high price is due to various factors like government regulations, production costs, and so on. Therefore, the unaffordable cost of gene therapies is limiting the viral vector & plasmid DNA market growth. The companies in the viral vectors and plasmid DNA market are focusing on the launch of viral vector assays to boost gene therapy research. Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells and viral vector assays is an investigative procedure on viral vector. For example, in November 2022, PerkinElmer, an American testing laboratories company, announced the launch of its "ready-to-use" adeno-associated virus vectors (AAV) detection kits to support researchers working on gene therapies for a variety of diseases. The viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer. In January 2020, Cognate Bioservices Inc., a US-based company skilled in cell and cell-mediated gene therapy products, acquired Cobra Biologics, which specialised in providing manufacturing services for plasmid DNA and viral vectors, for an undisclosed amount. The acquisition is expected to create a platform for the life cycle management of cell and gene therapy products. Cobra biologics is well established in the development and manufacture of a variety of viral vectors and DNA. The combined Cognate and Cobra expertise is expected to push both the businesses to a better position to respond to current and future market demand. North America is the largest region in the viral vectors and plasmid DNA market in 2022. The Middle East is expected to be the fastest growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the global viral vectors & plasmid DNA market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the viral vectors & plasmid DNA market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The viral vectors and plasmid DNA market consists of sales of adeno-associated viral, adenoviral, lentiviral, and retroviral. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The viral vectors & plasmid DNA market research report is one of a series of new reports from The Business Research Company that provides viral vectors & plasmid DNA market statistics, including viral vectors & plasmid DNA industry global market size, regional shares, competitors with a viral vectors & plasmid DNA market share, detailed viral vectors & plasmid DNA market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors & plasmid DNA industry. This viral vectors & plasmid DNA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

CRISPR is a gene-editing technology that allows researchers to alter DNA sequences and modify gene function. It is useful in gene editing. The main types of products in CRISPR technology market are design tools, plasmid and vector, CAS9 and G-RNA and delivery system products. CRISPR-Cas9 is a groundbreaking technology that allows geneticists and medical researchers to edit portions of the genome by removing, inserting, or changing DNA sequences. The different applications include genome editing or genetic engineering, genetically modified organisms, agricultural biotechnology, others and are used by several sectors such as industrial biotech, biological research, agricultural research, therapeutics and drug discovery. The global CRISPR technology market is segmented - 1) By Product Type: Design Tools, Plasmid And Vector, Cas9 And G-RNA, Delivery System Products 2) By Application: Genome Editing/ Genetic Engineering, Genetically Modified Organisms, Agricultural Biotechnology, Other Applications 3) By End-User: Industrial Biotech, Biological Research, Agricultural Research, Therapeutics And Drug Discovery The global CRISPR technology market size will grow from $1.33 billion in 2022 to $1.65 billion in 2023 at a compound annual growth rate (CAGR) of 24.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of global CRISPR technology is expected to grow to $3.77 billion in 2027 at a CAGR of 22.9%. The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc’s Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology market for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services. Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery PLC., Integrated DNA Technologies Inc. (Danaher), Origene Technologies Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc. and GeneCopoeia Inc. Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period. There is no existence of internationally agreed regulatory framework for gene editing products and countries are in the process of evaluating whether and to what extent current regulations are adequate for research conducted with gene editing and applications and products related to gene editing. The Court of Justice of the European Union ruled that it would treat gene-edited crops as genetically modified organisms, subject to stringent regulation. According to an article of 2020, in India, as per the National Guidelines for Stem Cell Research, genome modification including gene-editing by CRISPR-Cas9 technology of stem cells, germ-line stem cells or gamete and human embryos is restricted only to in-vitro studies. Thus, strict regulations by the government present a threat to the growth of the CRISPR technology market. Several advancements in CRISPR technology market are trending in the market during the period. Advancements in technology will help in reducing errors, limiting unintended effects, improving the accuracy of the tool, widening its applications, developing gene therapies and more. In 2020, astudy in Springer Nature stated that researchers have used enzyme engineering to boost the accuracy of the technique of error-prone CRISPR–Cas9 system to precisely target DNA without introducing as many unwanted mutations. The advancements in CRISPR technology will result in better tools that are capable of providing better outcomes. In March 2021, Integrated DNA Technologies (IDT), a US-based genomics solutions provider, acquired Swift Biosciences. The acquisition aimed at leveraging Swift's academic and clinical research in next-generation sequencing. Swift Biosciences is a US-based company involved in creating genomics kits to prepare Next-Generation Sequencing (NGS) libraries. North America was the largest region in the CRISPR technology market in 2022. Western Europe was the second largest region in the CRISPR technology market report. The regions covered in the CRISPR technology industry report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the CRISPR technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The CRISPR technology market includes revenue earned by CRISPR Screening Libraries, CRISPR Positive Controls, CRISPR Negative Controls, and Gene-specific Knockout Kits. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The CRISPR technology market research report is one of a series of new reports from The Business Research Company that provides CRISPR technology market statistics, including CRISPR technology industry global market size, regional shares, competitors with a CRISPR technology market share, detailed CRISPR technology market segments, market trends and opportunities, and any further data you may need to thrive in the CRISPR technology industry. This CRISPR technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vector control refers to a method for controlling vector-borne diseases spread through mammals, birds, insects, or other arthropods. The primary objective of vector control is to stop or eliminate the local spread of the virus, reduce disease vulnerability, and prevent secondary infections. These vector control methods can be chemical or non-chemical in nature. The main methods of vector control are chemical, physical and mechanical, biological, and others (radiation and environmental control services). Chemical vector control uses chemicals to control and prevent the spread of diseases. The chemical vector control is intended to impact mosquito densities, longevity and other transmission parameters. The vector control is designed to eliminate insects, rodents, and others (ticks and snails) and they are applied in residential, commercial, and industrial sectors. The global vector control market is segmented - 1) By Method of Control: Chemical, Physical and Mechanical, Biological, Other Method Of Control 2) By Vector Type: Insects, Rodents, Other Vector Types 3) By Application: Residential, Commercial, Industrial The global vector control market size grew from $17.91 billion in 2022 to $19.24 billion in 2023 at a compound annual growth rate (CAGR) of 7.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The market size of global vector control market is expected to grow to $24.64 billion in 2027 at a CAGR of 6.4%. The rising prevalence of vector-based diseases is expected to propel the vector control market. The increasing climate's impact and geographical distribution affect vector-borne disease transmission and spread. Due to such growing prevalence of vector-borne diseases has led to the adoption of vector control methods. These methods of preventing vector-based diseases is done by removing or dumping out water-holding containers and applying vector control methods such as pest control. For instance, In March 2020, according to a report from the World Health Organization, vector-borne diseases caused 700,000 deaths annually and accounted for 17% of all infectious diseases. Therefore, the rising prevalence of vector-based diseases is driving the growth of vector control market. Major players in the vector control market are Anticimex Group, Arrow Exterminators Inc., BASF SE, Bayer AG, Bell Laboratories Inc., Ecolab Inc., FMC Corporation, Rentokil Initial plc, Rollins Inc., Syngenta AG, The Terminix International Company Lp, Massey Services Inc., ADAMA, Liphatech, Inc., PelGar International, and Sumitomo Chemical Co Ltd. Technological advancements are a key trend driving the vector control market. The companies operating in the vector control market are increasingly focusing on developing innovative products to meet fast-growing industry demands and expand their business presence across the globe. For instance, in December 2021, Vectorcide International Ltd., a UK-based manufacturer of products for the reduction of vector-borne diseases, launched Vectorcide RP2 Coating, a green Eco-friendly mosquito repellent. Vectorcide RP2 Coating is a one-of-a-kind, safe, and highly effective indoor treatment. As it dries, the coating seals the capsules within the surface. (There are more than 20 billion capsules per square metre.) Typically, the capsules continue to release their active continuously over time through diffusion, and when the mosquito clings to the VC RP2 Coating treated surface, the insect's pin-like legs puncture the capsules. The entire insect is covered in several technically advanced ingredients, including the repellent, using the company's unique release mechanism. In December 2021, Rentokil Initial plc, UK-based commercial pest control and hygiene service provider, acquired Terminix Global Holdings, Inc. for $6.7 billion. Through this acquisition, Rentokil is focused on expanding the business to provide a solid foundation for future growth in North America and an appealing financial profile to support future growth, including continued investment in innovation and technology. Terminix Global Holdings, Inc is a US-based provider of pest-control solutions including vector control products. North America was the largest region in the vector control market share in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the global vector control market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vector control market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The vector control market consists of revenues earned by entities by providing vector control methods such as elimination or control of larval habitats and pesticide use to kill larvae. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The vector control market research report is one of a series of new reports from The Business Research Company that provides Vector control market statistics, including vector control industry global market size, regional shares, competitors with a vector control market share, detailed vector control market segments, market trends and opportunities, and any further data you may need to thrive in the vector control industry. This vector control market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bacterial and plasmid vectors refer to the means by which recombinant DNA is introduced into a host cell and are essential to molecular cloning. It is basically a process of creating DNA molecules and introducing them into a host cell. These vectors are used to deliver recombinant DNA into bacteria so they can express proteins. The main types of hosts in bacterial and plasmid vectors are E. coli expression vectors and other bacterial expression vectors. The E. coli expression system enables rapid recombinant protein expression and subsequent large-scale, cost-effective production. For non-glycosylated proteins, this technique is ideal for antigen expression and functional protein expression. The different applications include genetics, molecular biology, bioinformatics, and others and involve various sectors such as hospitals, homecare, specialty clinics, and others. The global bacterial and plasmid vectors market is segmented - 1) By Host Type: E.Coli Expression Vectors, Other Bacterial Expression Vectors 2) By Application: Genetics, Molecular Biology, Bioinformatics, Other Applications 3) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users The global bacterial & plasmid vectors market size grew from $0.57 billion in 2022 to $0.64 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of the global bacterial & plasmid vectors market is expected to grow from $1.02 billion in 2027 at a CAGR of 12.4%. Increasing the prevalence of cancer and infectious diseases is anticipated to boost the demand for the bacterial & plasmid vectors market over the coming years. Bacteria are used as vectors for the delivery of recombinant proteins into target cells for the treatment of cancer and various infectious diseases. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, in 2020, the total cancer burden in the world increased to 19.3 million new cases and is predicted to rise to 28.4 million new cancer cases in 2040. Therefore, the growing prevalence of cancer and various infectious diseases and the surging demand for bacterial and plasmid vectors for gene therapy are projected to propel market revenues for the bacterial and plasmid vectors market. Major players in the bacterial & plasmid vectors market report are Sigma-Aldrich Inc., ATUM, Qiagen, Promega Corporation, Thermo Fisher Scientific, Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories, and New England Biolabs. The high cost of gene therapy is expected to limit the growth of the bacterial & plasmid vector market during the forecast period. Gene therapy utilises genuine genes to prevent or treat diseases that utilise bacteria or plasmids as vectors. The cost of gene therapy treatments approved by the Food and Drug Administration is between $0.3 million and $2.1 million. Moreover, the cost of Luxturna gene therapy for certain inherited retinal diseases (IRDs) is $0.4 million per eye, and LentiGlobin, a gene therapy by Bluebird Bio designed to increase the levels of hemoglobin, costs around $2.1 million. Stringent government regulations, long approval processes, and production costs are the major factors leading to the high cost of gene therapy. Thus, the high cost of gene therapy is to hinder the bacterial & plasmid vector market growth in the near future. The focus areas for many companies in the bacterial and plasmid vectors market have shifted to increasing mergers and acquisitions to acquire more production capabilities. Large prime manufacturers are forming joint ventures or buying small or midsized companies to acquire new capabilities or gain access to new markets. For instance, Vectalys, a France-based company engaged in manufacturing and commercialising lentiviral vectors for gene delivery, and FlashCell, a company engineering non-integrating lentiviral delivered RNA therapeutics, announced their merger to create a new gene therapy company, Flash Therapeutics. In February 2021, Catalent, a US-based pharmaceutical company, acquired Delphi Genetics for an undisclosed amount. Through this acquisition, Catalent's growth of plasmid capabilities in the United States at its Rockville facility will be accelerated. Delphi Genetics is a Belgium-based contract development and manufacturing company specialising in plasmid DNA (pDNA) cell and gene therapy (CDMO). North America was the largest region in the bacterial & plasmid vectors market in 2022. The Middle East is expected to be the fastest growing region in the global bacterial & plasmid vectors market share during the forecast period. The regions covered in the bacterial & plasmid vectors market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the bacterial & plasmid vectors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The bacterial and plasmid vectors market includes revenues earned by entities by cloning, transferring, and manipulating genes. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the chain or as part of other products. The bacterial and plasmid vectors market research report is one of a series of new reports from The Business Research Company that provides bacterial and plasmid vectors market statistics, including bacterial and plasmid vectors industry global market size, regional shares, competitors with a bacterial and plasmid vectors market share, detailed bacterial and plasmid vectors market segments, market trends and opportunities, and any further data you may need to thrive in the bacterial and plasmid vectors industry. This bacterial and plasmid vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Thrust vector control (TVC), also known as thrust vectoring, refers to the capability of an airplane's rocket or another vehicle to regulate altitude or angular velocity by directing its forward momentum from its engine or motor. This system is used in aircraft to control the axial thrust and provide attitude control. The main types of thrust vector control are gimbal nozzle, thrusters, flex nozzle, rotating nozzle, and others. A thruster is a propellant device utilized by spaceships and watercraft for station holding, attitude control, reaction control, and long-duration, low-thrust acceleration. The various systems include thrust vector actuation systems, thrust vector injection systems, and thrust vector thruster systems that are used in launch vehicles, satellites, missiles, and fighter aircraft, which are used by space agencies and defense sectors. The global thrust vector control market is segmented - 1) By Type: Gimbal Nozzle, Thrusters, Flex Nozzle, Rotating Nozzle, Other Types 2) By System: Thrust Vector Actuation System, Thrust Vector Injection System, Thrust Vector Thruster System 3) By Application: Launch Vehicles, Satellites, Missiles, Fighter Aircraft 4) By End-User: Space Agencies, Defense The global thrust vector control market size is expected to grow from $10.74 billion in 2022 to $11.83 billion in 2023 at a compound annual growth rate (CAGR) of 10.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of thrust vector control market is expected to reach $16.84 billion in 2027 at a CAGR of 9.2%. The rising demand for corporate and military satellites is expected to propel the growth of the thrust vector control market going forward. Corporate satellites refer to those that are created and marketed for commercial, academic, non-profit, or civilian reasons (through commercial contracts) rather than military usage. A military satellite is a satellite that is launched into space to perform purposes such as transmissions, navigation, and surveillance connected to a range of military duties on the Earth's surface. The increasing need for commercial and military satellites enhances thrust vector control, which allows a rocket or launching vehicle to adjust its flight direction by varying the strength of its engine and is an essential component of the space or aerospace movement. For instance, in July 2022, according to the Space Foundation, a US-based non-profit advocacy group for the global space ecology, 72 rockets and 1,022 identifiable satellites were launched between January 2022 and June 2022. Furthermore, in June 2022, according to the Satellite Industry Association, a US-based leading domestic satellite operator represented in this trade organization, a total of 1,713 commercial satellites were deployed in 2021, an increase of more than 40% over 2020, while the space sector staged the most launches in history. There are predicted to be 4,852 satellites orbiting the Earth by the end of 2021, a 179 % increase over the preceding five years. Therefore, the rising demand for corporate and military satellites is driving the thrust vector control market. Major players in the thrust vector control market are General Electric Company, Raytheon Technologies Corporation, The Boeing Company, Bharat Dynamics Limited, Northrop Grumman, Honeywell International Inc., Hindustan Aeronautics Limited, BAE Systems, Safran S.A., Eaton Corporation plc, Thales Group, L3Harris Technologies Inc., Rolls-Royce Holdings plc, Kawasaki Heavy Industries Ltd., Israel Aerospace Industries, Pratt and Whitney, MBDA, Moog Inc., Woodward Inc, Aerojet Rocketdyne Holdings Inc., Sierra Nevada Corporation, JASC Corporation, SABCA (Sociétés Anonyme Belge de Constructions Aéronautiques), Almatech SA, Wickman Spacecraft and Propulsion Company, and Jansen Aircraft Systems Control Inc. The advancement of 3D printing is the key trend gaining popularity in the thrust vector control market. Major companies operating in thrust vector control are focused on developing innovative 3D products to strengthen their position in the market. For instance, in May 2023, Relativity Space, a US-based manufacturer of aerospace technologies, launched Terran 1. This was the first launch of a 100-foot-tall and 7.5-foot-wide test rocket composed completely of 3D-printed parts. Terran 1 highlighted a remarkable innovation with its utilization of nine engines crafted through additive manufacturing. These engines were constructed using a groundbreaking copper alloy, which exhibited the capability to withstand temperatures surpassing 6,000 degrees Fahrenheit. A 3D computer model is digitally sliced into thin layers in laser powder bed fusion. In June 2021, Astra, a US-based company that manufactures space propulsion and launches space vehicles acquired, Apollo Fusion for approximately $145 million. The acquisition of Apollo Fusion expands Astra's capabilities to deliver and manage spacecraft beyond low Earth orbit (LEO), to medium Earth orbit, orbit around the sun, and lunar orbits. Apollo Fusion, Inc., is a US-based company that manufactures electric propulsion engines that operates in the thrust vector control market. North America was the largest region in the thrust vector control market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in thrust vector control report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the thrust vector control market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The thrust vector control market consists of sales of electromechanical TVC systems, electrohydraulic TVC systems, electro hydrostatic TVC systems, electromechanical actuators, and modular control electronics units. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The thrust vector control market research report is one of a series of new reports from The Business Research Company that provides thrust vector control market statistics, including thrust vector control industry global market size, regional shares, competitors with a thrust vector control market share, detailed thrust vector control market segments, market trends, and opportunities, and any further data you may need to thrive in the thrust vector control industry. This thrust vector control market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.